Skip to main content
zenodorestricted

Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a ''real-world'' chart review study

<p>Adjunctive vortioxetine for SSRI-resistant major<br> depressive disorder: a &lsquo;&lsquo;real-world&rsquo;&rsquo; chart review study</p> <p>Objective: Selective serotonin reuptake inhibitors (SSRIs) are the cornerstone of treatment of major<br> depressive disorder (MDD). However, non-response is common, often necessitating combination<br> strategies. The present study assessed the efficacy of vortioxetine as an add-on therapy in patients<br> with SSRI-resistant MDD.<br> Methods: The charts of 36 adult outpatients with DSM-IV-TR MDD who had not achieved a response<br> after at least 8 weeks of treatment with an SSRI were reviewed retrospectively. Subjects were treated<br> with vortioxetine (5-20 mg/day) for 8 weeks added to the current SSRI. The main outcome measures<br> were change from baseline in total Hamilton Scale for Depression (HAM-D) score and the rate of<br> response (a 50% or greater reduction in HAM-D score and a Clinical Global Impression - Improvement<br> module [CGI-I] score of 1 or 2 at endpoint). HAM-D scores p 7 were considered as remission.<br> Additional outcome measures included the Snaith-Hamilton Pleasure Scale (SHAPS) and the Scale<br> for Suicide Ideation (SSI).<br> Results: 32 patients completed the 8 weeks of treatment. At 8 weeks, a significant reduction in HAM-D<br> score was observed (p p 0.001), with response obtained by 41.7% and remission by 33.3% of<br> patients. Significant reductions in SHAPS and SSI were also observed (p p 0.001 for both scales).<br> Conclusions: Adjunctive vortioxetine may be useful and well-tolerated in stage I treatment-resistant<br> depression. However, the limitations of this study (such as small sample size, absence of<br> randomization and control group, retrospective design, etc.) must be considered.</p>

ShareScore

12/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
4
Harmonization
4
Access
0
Reuse readiness
0
Engagement
4

Dataset details

Repository
zenodo
Published
January 3, 2022
License
Not reported
DOI
10.5281/zenodo.5819137

Scored with release 0.9.0

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.